Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Saturday morning. The firm issued a hold rating on the stock.

Other equities analysts have also issued reports about the company. HC Wainwright decreased their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital decreased their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th.

Ekso Bionics Trading Up 4.3 %

EKSO opened at $0.61 on Friday. The firm’s fifty day moving average is $0.79 and its two-hundred day moving average is $1.00. The firm has a market cap of $13.31 million, a PE ratio of -0.93 and a beta of 1.43. Ekso Bionics has a twelve month low of $0.50 and a twelve month high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. During the same period in the previous year, the business posted ($0.24) EPS. Equities research analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.